ClinicalTrials.gg
CompletedNCT00371150Updated Apr 16, 2012Results posted

Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection

A Phase 4 interventional study of Entecavir in Hepatitis B Infection, sponsored by Bristol-Myers Squibb. Completed at 27 sites in 5 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2012-04-16.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
131
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies testing entecavir in Hepatitis B — 6 open to participants now, 9 under way, none of them phase 3. entecavir · Hepatitis B.

Enrollment
15th of 36
131 · median 106
Started
2006
with 1 other
Phase 4
20 of 37
5 open now
Registered
5th of 37
by date
Lead sponsor
6 of 37
Bristol-Myers Squibb

Among the 37 studies testing entecavir in Hepatitis B, this one is the 15th largest by enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2006, is one of 20 in phase 4, and was the 5th registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

6 of the 37 studies testing entecavir in Hepatitis B are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing entecavir in Hepatitis B, or all of them as a file.
02

Study summary

The purpose of this clinical research study is to develop observational clinical experience with the use of entecavir in participants who are either of Black/African-American race or of Hispanic ethnicity.

03

Conditions studied

  • Hepatitis B Infection

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic infection, with either HBeAg-positive (HBeAb-negative) or HBeAg-negative (HBeAb-positive) disease
  • Black/African American Race and/or Hispanic ethnicity
  • Nucleoside/tide-naive
  • Males or females ≥ 16 years of age (or minimum age required in a given country)
  • Compensated liver function
  • of 1.3 to 10 x (ULN)
  • No Co-infection with (HIV), virus (HCV) or hepatitis D virus (HDV)

Exclusion criteria

Exclusion Criteria

  • Women of (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 6 weeks after study medication has been discontinued
  • Women who are pregnant or breastfeeding
  • Women with a positive pregnancy test on enrollment or prior to study drug administration
  • Evidence of decompensated cirrhosis including but not limited to: variceal bleeding; hepatic encephalopathy; or ascites requiring management with diuretics or paracentesis
  • Recent history of pancreatitis (resolution of any recent pancreatitis must be documented by normal lipase at least 12 weeks prior to the first dose of study medication)
  • Currently abusing illegal drugs or alcohol sufficient, in the investigator's opinion, to prevent adequate compliance with study therapy or to increase the risk of hepatotoxicity or pancreatitis
  • Other serious medical conditions that might preclude completion of this study or that require chronic administration of prohibited medications
  • Serum creatinine > 1.5 mg/dL
  • \< 10.0 g/dL
  • count \< 70,000/mm3
  • \< 1200 cells/mm3
  • Serum alpha fetoprotein (AFP) level > 100 ng/mL. If the AFP level is between 21 and 100 ng/mL, it must be repeated. If the repeat AFP level is between 21 and 100 ng/mL and if ultrasonography or computerized tomography (CT) of the liver performed prior to the first dose of study medication does not demonstrate a focal lesion suggestive of carcinoma, the subject may be dosed in the study
  • Known history of allergy to nucleoside analogues
  • Any prior therapy with Entecavir
  • Any prior or concomitant use of nucleoside or nucleotide analogue antiviral agents with activity against (e.g., ETV, lamivudine (LVD), tenofovir [TDF], emtricitabine (FTC), clevudine, telbivudine [LdT], famciclovir), or any other experimental anti-HBV antiviral agent
  • Therapy with interferon, thymosin alpha or other immunostimulators within 24 weeks of enrollment (i.e., dosing) into this study
  • Subjects who require chronic administration of concomitant medications which cause or which are associated with a high rate of nephrotoxicity or hepatotoxicity, or which affect renal excretion, should not be enrolled in this study
  • Unable to tolerate oral medication
  • Poor peripheral venous access
  • Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    Arm1

    Drug: Entecavir

Interventions

  • Tablets, Oral, 0.5 mg, once daily, up to 52 weeks

    Also known as: Baraclude, BMS-200475

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) < 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 48

    HBV DNA assessments were performed using the Roche COBAS® TaqMan AmpliPrep assay. HBV DNA \< 50 IU/mL = approximately \<300 copies/mL.

    Time frame: Week 48 of ETV treatment

Secondary outcomes

  1. Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 48

    HBV DNA assessments were performed using the Roche COBAS® TaqMan AmpliPrep assay. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection.

    Time frame: Week 48

  2. Percentage of Participants With HBV DNA by PCR Category at Week 48

    HBV DNA assessments were performed using the Roche COBAS® TaqMan AmpliPrep assay.

    Time frame: Week 48

  3. Percentage of Participants With Virologic Rebound Through Week 48 While on Continued Dosing With ETV

    Virologic rebound is defined as a confirmed increase of ≥ 1 log10 in HBV DNA from the participant's nadir value (2 sequential HBV DNA measurements or last on-treatment measurement)

    Time frame: through Week 48

  4. Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48

    ALT normalization=ALT level being less than or equal to 1 times the upper limit of normal (ULN). ULN for ALT is 37 U/L.

    Time frame: Week 48

  5. Percentage of Participants With Confirmed HBeAg Loss at Week 48 (for HBeAg-positive Participants Only)

    HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week

    Time frame: Week 48

  6. Percentage of Participants With HBeAg Seroconversion at Week 48 (for HBeAg-positive Participants Only)

    HBeAg is a hepatitis B viral protein. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb).

    Time frame: Week 48

  7. Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48

    HBsAg = a part of the hepatitis B virus that, when in the blood, is a marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week.

    Time frame: Week 48

  8. Percentage of Participants With HBsAg Seroconversion at Week 48

    HBsAg = a part of the hepatitis B virus that, when in the blood, is a of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb.

    Time frame: Week 48

  9. Mean log10 Reduction From Baseline in HBV DNA at Week 48

    HBV DNA was analyzed by PCR, using the Roche COBAS®TaqMan TaqMan AmpliPrep assay. Reduction in log10 HBV count=reduced viral load.

    Time frame: baseline, Week 48

  10. Percentage of Participants With HBV DNA < Other IU Cut-off Points That May be Clinically Relevant at the Time of Data Analysis

    Time frame: Week 48

  11. Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations From Study Drug Due to Adverse Events

    AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded.

    Time frame: From enrollment through Week 52 + 5 days

  12. Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment (OF): Hematology

    Criteria for hematology abnormalities were graded using the modified WHO grading system. Hemoglobin: \<=11.0 g/dL; White Blood Cells: \<4000/mm\^3; Absolute Neutrophils (includes absolute bands): \<1500/mm\^3; Platelets: \<=99,000/mm\^3; International Normalized Ratio: ≥ 1.5 and ≥ 0.5 from baseline.

    Time frame: OT: From start of study therapy through Week 52 + 5 days; OF= End of OT period + 24-week follow-up

  13. Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment (OF) : Serum Chemistry

    The modified World Health Oranization(WHO)grading system was used to grade the abnormalities. ULN=upper limit of normal. Alanine aminotransferase:\>1.25xULN, Aspartate aminotransferase:\>1.25xULN, Alkaline Phosphatase:\>1.25xULN, Total Bilirubin:\>1.1xULN, Serum Lipase:\>1.10xULN, Creatinine:\>1.1xULN, Blood Urea Nitrogen:1.25xULN, Hyperglycemia:\>116 mg/dL, Hypoglycemia:\<64 mg/dL, Hyponatremia:\<132meq/L, Hypokalemia:\<3.4 meq/L, Albumin:≥1g/dL decrease from baseline, \<3 g/dL; Hypernatremia:\>148 meq/L, Hyperkalemia:\>5.6 meq/L, Hypokalemia:\<3.4 meq/L, Hyperchloremia:\>113 meq/L, Hypochloremia:\<93 meq/L

    Time frame: OT: From start of study therapy through Week 52 + 5 days; OF= End of OT period + 24-week follow-up

07

Results

Posted Apr 16, 2012

Participant flow

A total of 131 participants were enrolled at 27 sites.

Participant flow — Overall Study
MilestoneBlack/ African AmericanHispanic
Started406
Discontinued prior to week 48 visit11
Discontinued at or after week 48 visit21
Completed374
Not completed32
Withdrew: Lost to follow-up32

Outcome measures

SecondaryPercentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 48

HBV DNA assessments were performed using the Roche COBAS® TaqMan AmpliPrep assay. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 48
percentage of participantsBlack / African AmericanTotal
Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 4812.5 (NA to NA)13.0 (3.3 to 22.8)
SecondaryPercentage of Participants With HBV DNA by PCR Category at Week 48

HBV DNA assessments were performed using the Roche COBAS® TaqMan AmpliPrep assay.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA by PCR Category at Week 48
percentage of participantsBlack / African AmericanTotal
<50 IU/mL (< 300 copies/mL)72.569.6
50 to <172 IU/mL (300 to < 103 copies/mL)00
172 to <1720 IU/mL (103 to < 104 copies/mL)10.010.9
1720 to <17200 IU/mL (104 to < 105 copies/mL)5.04.3
≥17,200 IU/mL (≥105 copies/mL)00
Missing12.515.2
SecondaryPercentage of Participants With Virologic Rebound Through Week 48 While on Continued Dosing With ETV

Virologic rebound is defined as a confirmed increase of ≥ 1 log10 in HBV DNA from the participant's nadir value (2 sequential HBV DNA measurements or last on-treatment measurement)

Time frame:
through Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Rebound Through Week 48 While on Continued Dosing With ETV
percentage of participantsBlack / African AmericanTotal
Percentage of Participants With Virologic Rebound Through Week 48 While on Continued Dosing With ETV00
SecondaryPercentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48

ALT normalization=ALT level being less than or equal to 1 times the upper limit of normal (ULN). ULN for ALT is 37 U/L.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48
percentage of participantsBlack / African AmericanTotal
Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 4867.567.4
SecondaryPercentage of Participants With Confirmed HBeAg Loss at Week 48 (for HBeAg-positive Participants Only)

HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Confirmed HBeAg Loss at Week 48 (for HBeAg-positive Participants Only)
percentage of participantsBlack / African AmericanTotal
Percentage of Participants With Confirmed HBeAg Loss at Week 48 (for HBeAg-positive Participants Only)50.053.8
SecondaryPercentage of Participants With HBeAg Seroconversion at Week 48 (for HBeAg-positive Participants Only)

HBeAg is a hepatitis B viral protein. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb).

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBeAg Seroconversion at Week 48 (for HBeAg-positive Participants Only)
percentage of participantsBlack / African AmericanTotal
Percentage of Participants With HBeAg Seroconversion at Week 48 (for HBeAg-positive Participants Only)40.946.2
SecondaryPercentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48

HBsAg = a part of the hepatitis B virus that, when in the blood, is a marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48
percentage of participantsBlack / African AmericanTotal
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 485.06.5
SecondaryPercentage of Participants With HBsAg Seroconversion at Week 48

HBsAg = a part of the hepatitis B virus that, when in the blood, is a of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Seroconversion at Week 48
percentage of participantsBlack / African AmericanTotal
Percentage of Participants With HBsAg Seroconversion at Week 482.54.3
SecondaryMean log10 Reduction From Baseline in HBV DNA at Week 48

HBV DNA was analyzed by PCR, using the Roche COBAS®TaqMan TaqMan AmpliPrep assay. Reduction in log10 HBV count=reduced viral load.

Time frame:
baseline, Week 48
Reported as:
Mean · log10 IU/mL
Mean log10 Reduction From Baseline in HBV DNA at Week 48
log10 IU/mLBlack / African AmericanTotal
Baseline7.1 ± 0.267.0 ± 0.25
HBV DNA at Week 481.88 ± 0.1001.87 ± 0.091
Change from baseline-5.22 ± 0.249-5.18 ± 0.231
SecondaryPercentage of Participants With HBV DNA < Other IU Cut-off Points That May be Clinically Relevant at the Time of Data Analysis
Time frame:
Week 48
Reported as:
Number · percentage of participants

No measurements were reported for this outcome.

SecondaryNumber of Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations From Study Drug Due to Adverse Events

AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded.

Time frame:
From enrollment through Week 52 + 5 days
Reported as:
Number · participants
Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations From Study Drug Due to Adverse Events
participantsBlack / African AmericanHispanicTotal
Deaths000
SAEs314
Discontinuations Due to AEs000
Any AE33538
Grade 3 - 4 AEs516
Related AEs16016
Grade 2 - 4 Related AEs505
SecondaryNumber of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment (OF): Hematology

Criteria for hematology abnormalities were graded using the modified WHO grading system. Hemoglobin: \<=11.0 g/dL; White Blood Cells: \<4000/mm\^3; Absolute Neutrophils (includes absolute bands): \<1500/mm\^3; Platelets: \<=99,000/mm\^3; International Normalized Ratio: ≥ 1.5 and ≥ 0.5 from baseline.

Time frame:
OT: From start of study therapy through Week 52 + 5 days; OF= End of OT period + 24-week follow-up
Reported as:
Number · participants
Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment (OF): Hematology
participantsBlack / African AmericanTotal
Hemoglobin-OT12
Hemoglobin-OF; n=26 , 2900
White Blood Cells-OT1518
White Blood Cells-OF; n=26 , 2978
Neutrophils -OT1313
Neutrophils-OF; n=26 , 2644
Platelets-OT44
Platelets-OF; n=26 , 2900
International Normalized Ratio-OT1823
International Normalized Ratio-OF; n=26 , 2944
PrimaryPercentage of Participants With HBV Deoxyribonucleic Acid (DNA) < 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 48

HBV DNA assessments were performed using the Roche COBAS® TaqMan AmpliPrep assay. HBV DNA \< 50 IU/mL = approximately \<300 copies/mL.

Time frame:
Week 48 of ETV treatment
Reported as:
Number · percentage of participants
Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) < 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 48
percentage of participantsBlack / African AmericanTotal
Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) < 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 4872.5 (NA to NA)69.6 (56.3 to 82.9)
SecondaryNumber of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment (OF) : Serum Chemistry

The modified World Health Oranization(WHO)grading system was used to grade the abnormalities. ULN=upper limit of normal. Alanine aminotransferase:\>1.25xULN, Aspartate aminotransferase:\>1.25xULN, Alkaline Phosphatase:\>1.25xULN, Total Bilirubin:\>1.1xULN, Serum Lipase:\>1.10xULN, Creatinine:\>1.1xULN, Blood Urea Nitrogen:1.25xULN, Hyperglycemia:\>116 mg/dL, Hypoglycemia:\<64 mg/dL, Hyponatremia:\<132meq/L, Hypokalemia:\<3.4 meq/L, Albumin:≥1g/dL decrease from baseline, \<3 g/dL; Hypernatremia:\>148 meq/L, Hyperkalemia:\>5.6 meq/L, Hypokalemia:\<3.4 meq/L, Hyperchloremia:\>113 meq/L, Hypochloremia:\<93 meq/L

Time frame:
OT: From start of study therapy through Week 52 + 5 days; OF= End of OT period + 24-week follow-up
Reported as:
Number · participants
Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment (OF) : Serum Chemistry
participantsBlack / African AmericanTotal
Alanine aminotransferase-OT3743
Alanine aminotransferase-OF; n=26 , 2934
Aspartate aminotransferase-OT3338
Aspartate aminotransferase-OF; n=26 , 2923
Alkaline Phosphatase-OT33
Alkaline Phosphatase-OF; n=26 , 2911
Albumin-OT35
Albumin-OF; n=26 , 2900
Total Bilirubin-OT77
Total Bilirubin-OF; n=26 , 2934
Serum Lipase-OT1214
Serum Lipase-OF; n=26 , 2911
Creatinine-OT33
Creatinine-OF; n=26 , 2900
Blood Urea Nitrogen-OT22
Blood Urea Nitrogen-OF; n=26 , 2900
Hyperglycemia-OT1415
Hyperglycemia-OF; n=26 , 2955
Hypoglycemia-OT55
Hypoglycemia-OF; n=26 , 2911
Hypernatremia-OT00
Hypernatremia-OF; n=26 , 2900
Hyponatremia-OT33
Hyponatremia-OF; n=26 , 2901
Hyperkalemia-OT00
Hyperkalemia-OF; n=26 , 2900
Hypokalemia-OT33
Hypokalemia-OF; n=26 , 2900
Hyperchloremia-OT00
Hyperchloremia-OF; n=26 , 2900
Hypochloremia-OT00
Hypochloremia-OF; n=26 , 2900

Adverse events

Collected over 52 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Entecavir (ETV)—4/46 (8.7%)21/46 (45.7%)
Most frequent serious events
Most frequent serious events
EventEntecavir (ETV)
ALANINE AMINOTRANSFERASE INCREASEDInvestigations1/46
RENAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)1/46
PYREXIAGeneral disorders1/46
ANGINA PECTORISCardiac disorders1/46
ASCITESGastrointestinal disorders1/46
BLOOD GLUCOSE ABNORMALInvestigations1/46
HEADACHENervous system disorders1/46
LEUKOCYTOSISBlood and lymphatic system disorders1/46
LOBAR PNEUMONIAInfections and infestations1/46
PNEUMONIAInfections and infestations1/46
Most frequent other events
Showing 10 of 12
Most frequent other events
EventEntecavir (ETV)
HEADACHENervous system disorders8/46
ABDOMINAL PAINGastrointestinal disorders6/46
DIARRHOEAGastrointestinal disorders5/46
PYREXIAGeneral disorders4/46
BACK PAINMusculoskeletal and connective tissue disorders4/46
FATIGUEGeneral disorders4/46
INFLUENZAInfections and infestations4/46
NAUSEAGastrointestinal disorders4/46
SOMNOLENCENervous system disorders3/46
URINARY TRACT INFECTIONInfections and infestations3/46

Baseline characteristics

Age Continuous
Age Continuous(years)Black/ African AmericanHispanicTotal
Median39.0 (22 to 67)48.0 (29 to 69)40.0 (22 to 69)
Sex: Female, Male
Sex: Female, Male(Participants)Black/ African AmericanHispanicTotal
Female9211
Male31435
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Black/ African AmericanHispanicTotal
Hispanic / Latino066
Not Hispanic / Latino18018
Missing22022
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Black/ African AmericanHispanicTotal
Black/ African American40040
White066
Region of Enrollment
Region of Enrollment(participants)Black/ African AmericanHispanicTotal
Brazil21021
Mexico022
South Africa303
United States16420
Hepatitis B surface antigen (HBsAg) status at baseline
Hepatitis B surface antigen (HBsAg) status at baseline(participants)Black/ African AmericanHispanicTotal
Positive40444
Negative000
Missing022
Hepatitis B e antigen (HBeAg) status at baseline
Hepatitis B e antigen (HBeAg) status at baseline(participants)Black/ African AmericanHispanicTotal
Positive22426
Negative18220
Hepatitis B e antibody (HBeAb) at baseline
Hepatitis B e antibody (HBeAb) at baseline(participants)Black/ African AmericanHispanicTotal
Positive19221
Negative21425

3 further baseline measures are reported on the registry.

08

Study locations

27 sites
  • Alabama Liver & Digestive Specialists (Alds)
    Montgomery, Alabama 36116, United States
  • University Of Arizona
    Tucson, Arizona 85724, United States
  • George Washington University Medical Center
    Washington, District of Columbia 20037, United States
  • University Of Miami
    Miami, Florida 33136, United States
  • Empire International Research
    Miami, Florida 33144, United States
  • University Of Chicago
    Chicago, Illinois 60637, United States
  • Banks Hepatology Institute, Pc
    College Park, Maryland 20740, United States
  • Brigham And Women'S Hospital
    Boston, Massachusetts 02115, United States
  • L L C Bda The Research Institute
    Springfield, Massachusetts 01107, United States
  • Va New York Harbor Healthcare System
    New York, New York 10010, United States
  • Westchester Digestive Disease Group, Llp
    Yonkers, New York 10701, United States
  • Albert Einstein Healthcare Network
    Philadelphia, Pennsylvania 19141, United States
  • Alamo Medical Research
    San Antonio, Texas 78215, United States
  • Hunter Holmes Mcguire D V A M C
    Richmond, Virginia 23249, United States
  • Local Institution
    Salvador, Bahia 40110, Brazil
  • Local Institution
    Belo Horizonte - Mg, Minas Gerais 30150, Brazil
  • Local Institution
    Rio De Janeiro - Rj, Rio De Janeiro 20210, Brazil
  • Local Institution
    Campinas, Sao Paulo 13083, Brazil
  • Local Institution
    Sao Paulo - Sp, Sao Paulo 01246, Brazil
  • Local Institution
    Df, Distrito Federal 14000, Mexico
  • Local Institution
    Guadalajara, Jalisco 44270, Mexico
  • Local Institution
    Guadalajara, Jalisco 44280, Mexico
  • Local Institution
    Guadalajara, Jalisco 44650, Mexico
  • Local Institution
    Zapopan, Jalisco 45150, Mexico
  • Local Institution
    Santurce, 00909, Puerto Rico
  • Local Institution
    Belville, Western Cape 7350, South Africa
  • Local Institution
    Goodwood, Western Cape 7460, South Africa
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2006
First posted
Sep 1, 2006
Start
Nov 2006
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Results first posted
Apr 16, 2012
Last update
Apr 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00371150
Responsible party
Sponsor
First posted
Sep 1, 2006
Start date
Nov 2006
Primary completion
Mar 2011
Completion
Mar 2011
Results posted
Apr 16, 2012
Last update
Apr 16, 2012

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entecavir

Start the discussion